JP2007517071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007517071A5 JP2007517071A5 JP2006549289A JP2006549289A JP2007517071A5 JP 2007517071 A5 JP2007517071 A5 JP 2007517071A5 JP 2006549289 A JP2006549289 A JP 2006549289A JP 2006549289 A JP2006549289 A JP 2006549289A JP 2007517071 A5 JP2007517071 A5 JP 2007517071A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- effective amount
- therapeutically effective
- acceptable carrier
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000003937 drug carrier Substances 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 4
- 230000000394 mitotic effect Effects 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 2
- 101710149643 Integrin alpha-IIb Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 229940125683 antiemetic agent Drugs 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000012820 cell cycle checkpoint Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 239000000824 cytostatic agent Substances 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- 230000036457 multidrug resistance Effects 0.000 claims 2
- 208000004235 neutropenia Diseases 0.000 claims 2
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 2
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000007755 survival signaling Effects 0.000 claims 2
- 239000003558 transferase inhibitor Substances 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 1
- 102000010638 Kinesin Human genes 0.000 claims 1
- 108010063296 Kinesin Proteins 0.000 claims 1
- 229940124179 Kinesin inhibitor Drugs 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940123468 Transferase inhibitor Drugs 0.000 claims 1
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 201000004962 larynx cancer Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 201000007275 lymphatic system cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000020347 spindle assembly Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical group C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 claims 1
- 229960003425 tirofiban Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53137203P | 2003-12-19 | 2003-12-19 | |
| PCT/US2004/042070 WO2005065183A2 (en) | 2003-12-19 | 2004-12-15 | Mitotic kinesin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517071A JP2007517071A (ja) | 2007-06-28 |
| JP2007517071A5 true JP2007517071A5 (https=) | 2008-02-21 |
Family
ID=34748759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549289A Withdrawn JP2007517071A (ja) | 2003-12-19 | 2004-12-15 | 有糸分裂キネシン阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070060601A1 (https=) |
| EP (1) | EP1696927A4 (https=) |
| JP (1) | JP2007517071A (https=) |
| CN (1) | CN1893951A (https=) |
| AU (1) | AU2004311737A1 (https=) |
| CA (1) | CA2549641A1 (https=) |
| WO (1) | WO2005065183A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007536239A (ja) * | 2004-05-06 | 2007-12-13 | スミスクライン・ビーチャム・コーポレイション | カルシウム受容体アンタゴニスト化合物 |
| WO2006045010A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| CA2630117A1 (en) * | 2005-11-22 | 2007-05-31 | Smithkline Beecham Corporation | Calcilytic compounds |
| EP2079739A2 (en) * | 2006-10-04 | 2009-07-22 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| CN101531638B (zh) * | 2008-03-13 | 2011-12-28 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| SI2346837T1 (sl) | 2008-06-26 | 2015-05-29 | Resverlogix Corporation | Postopki pripravljanja kinazolinonskih derivatov |
| CN101628913B (zh) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| KR101913109B1 (ko) | 2009-03-18 | 2018-10-31 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| CA2851996C (en) | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| CN107417628A (zh) * | 2017-06-28 | 2017-12-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 二芳基喹唑啉酮类化合物、其制备方法及其医药用途以及包含该类化合物的药物组合物 |
| CN110041272B (zh) * | 2019-05-29 | 2020-10-30 | 中国人民解放军军事科学院军事医学研究院 | 2-(2-氯苯基)喹唑啉-4(3h)-酮类衍生物及其制备方法和用途 |
| CN110041273B (zh) * | 2019-05-29 | 2020-10-20 | 中国人民解放军军事科学院军事医学研究院 | 2-(2-氯-4-甲基苯基)喹唑啉-4(3h)-酮类化合物及其医药用途 |
| IL302807A (en) | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| PE20250609A1 (es) | 2021-12-03 | 2025-02-26 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3257397A (en) * | 1963-07-26 | 1966-06-21 | Rexall Drug Chemical | Substituted 2, 3-dihydro-4(1h)-quinazolinones |
| US3231572A (en) * | 1963-08-05 | 1966-01-25 | Miles Lab | 3-substituted-4-quinazolones |
| DE1670416A1 (de) * | 1966-12-30 | 1971-02-11 | Chem Fab Von Heyden Gmbh Muenc | Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten |
| US3463778A (en) * | 1967-01-13 | 1969-08-26 | Squibb & Sons Inc | Substituted 2,3-dihydro-4(1h)-quinazolinones |
| DE3166627D1 (en) * | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
| DE3717034A1 (de) * | 1987-05-21 | 1988-12-08 | Basf Ag | Photopolymerisierbare aufzeichnungsmaterialien sowie photoresistschichten und flachdruckplatten auf basis dieser aufzeichnungsmaterialien, sowie neue chinazolon-4-verbindungen |
| JP2000501086A (ja) * | 1995-11-24 | 2000-02-02 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | ピリドピリミジン |
| US5948775A (en) * | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6479499B1 (en) * | 2000-06-28 | 2002-11-12 | National Science Council | 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions |
| EP1513820A4 (en) * | 2002-05-23 | 2006-09-13 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
-
2004
- 2004-12-15 CA CA002549641A patent/CA2549641A1/en not_active Abandoned
- 2004-12-15 CN CNA2004800376917A patent/CN1893951A/zh active Pending
- 2004-12-15 US US10/582,823 patent/US20070060601A1/en not_active Abandoned
- 2004-12-15 AU AU2004311737A patent/AU2004311737A1/en not_active Abandoned
- 2004-12-15 JP JP2006549289A patent/JP2007517071A/ja not_active Withdrawn
- 2004-12-15 WO PCT/US2004/042070 patent/WO2005065183A2/en not_active Ceased
- 2004-12-15 EP EP04814275A patent/EP1696927A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517071A5 (https=) | ||
| JP2008527038A5 (https=) | ||
| Hu et al. | Mechanisms of drug resistance in colon cancer and its therapeutic strategies | |
| Haefner | NF-κB: arresting a major culprit in cancer | |
| Soares et al. | Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells | |
| Serafin et al. | Drug repositioning in oncology | |
| Abdelaleem et al. | Prospects for repurposing CNS drugs for cancer treatment. | |
| Jin et al. | Curaxin CBL0137 exerts anticancer activity via diverse mechanisms | |
| Piperdi et al. | Bortezomib: understanding the mechanism of action | |
| JP2013504582A5 (https=) | ||
| PT1307197E (pt) | Composicoes para o tratamento do cancro compreendendo um inibidor de topoisomerase e talidomida | |
| NZ621972A (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
| JP2006503919A5 (https=) | ||
| Kumar et al. | Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats | |
| FR2869540B1 (fr) | Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers | |
| PH12012500504A1 (en) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer | |
| RU2351330C2 (ru) | Применение эпотилонов в лечении заболеваний головного мозга, ассоциированных с пролиферативными процессами | |
| McLaughlin et al. | Modulation of the opioid growth factor ([Met5]‐enkephalin)–opioid growth factor receptor axis: Novel therapies for squamous cell carcinoma of the head and neck | |
| JP2009539994A5 (https=) | ||
| Eberli et al. | Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells | |
| RU2010109452A (ru) | Способы и композиции, предназначенные для лечения раковых заболеваний | |
| CY1114686T1 (el) | Χρηση toy ck2 αναστολεα για την θεραπεια και χημειοευαισθητοποιηση των ανθεκτικων σε αντικαρκινικα φαρμακα ογκων | |
| Srikumar et al. | Potential use of flavopiridol in treatment of chronic diseases | |
| Sharma | Synthetic and natural compounds as anti-cancer agents–a review | |
| JP2008527039A5 (https=) |